Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: Interim results of an open-label extension study

Epilepsy and Behavior

Volumn 25, Issue 4, 2012, Pages 687-694

  Ng, Yu Tze ^a   Conry, Joan ^b   Paolicchi, Juliann ^c   Kernitsky, Lydia ^d   Mitchell, Wendy ^e   Drummond, Rebecca ^f   Isojarvi, Jouko ^f   Lee, Deborah ^f   Owen, Randall ^f  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL CENTER   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^e CHILDREN S HOSPITAL LOS ANGELES   (United States)

^f LUNDBECK RESEARCH USA   (United States)

Author keywords

Antiepileptic drug; Benzodiazepine; Clobazam; Dosing; Drop seizures; Efficacy; Lennox Gastaut syndrome; Open label extension trial; Safety

Indexed keywords

CLOBAZAM; DIAZEPAM; ETIRACETAM; FELBAMATE; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGGRESSION; ARTICLE; CHILD; CONSTIPATION; CONVULSION; DEHYDRATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SAFETY; EPILEPTIC STATE; FALLING; FEMALE; FEVER; HUMAN; KETOGENIC DIET; LENNOX GASTAUT SYNDROME; LONG TERM CARE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OTITIS MEDIA; PNEUMONIA; PRESCHOOL CHILD; SCHOOL CHILD; SEDATION; SEIZURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGUS NERVE STIMULATION;

ADOLESCENT; ADULT; ANTICONVULSANTS; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INTELLECTUAL DISABILITY; MALE; MIDDLE AGED; SPASMS, INFANTILE; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871719328     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.09.039     Document Type: Article

References (16)

1. Arzimanoglou A., French J., Blume W.T., et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009, 8:82-93.
2. Chevrie J.J., Aicardi J. Childhood epileptic encephalopathy with slow spike-wave. A statistical study of 80 cases. Epilepsia 1972, 13:259-271.
3. Camfield P.R. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia 2011, 52(Suppl. 5):3-9.
4. Montouris G.D. Rational approach to treatment options for Lennox-Gastaut syndrome. Epilepsia 2011, 52(Suppl. 5):10-20.
5. Arzimanoglou A., Resnick T. All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome. but many do. Epileptic Disord 2011, 13(Suppl. 1):S3-S13.
6. Ng Y.T., Collins S.D. Clobazam. Neurotherapeutics 2007, 4:138-144.
7. Conry J.A., Ng Y.T., Paolicchi J.M., et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 2009, 50:1158-1166.
8. Ng Y.T., Conry J.A., Drummond R., Stolle J., Weinberg M.A. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011, 77:1473-1481.
9. Canadian Clobazam Cooperative Group Clobazam in treatment of refractory epilepsy: the Canadian experience. A retrospective study. Epilepsia 1991, 32:407-416.
10. Dodson W.E. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993, 34(Suppl. 7):S18-S24.
11. Glauser T., Kluger G., Sachdeo R., Krauss G., Perdomo C., Arroyo S. Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox-Gastaut syndrome. Presented at: 26th International Epilepsy Conference. Epilepsia 2005, 46(Suppl. 6):408.
12. Guberman A., Couture M., Blaschuk K., Sherwin A. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci 1990, 17:311-316.
13. Riss J., Cloyd J., Gates J., Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand 2008, 118:69-86.
14. Pellock J.M. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 1999, 21:225-239.
15. Pellock J.M., Faught E., Leppik I.E., Shinnar S., Zupanc M.L. Felbamate: consensus of current clinical experience. Epilepsy Res 2006, 71:89-101.
16. Guberman A.H., Besag F.M., Brodie M.J., et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999, 40:85-91.